Clinical trial
Phase I Study to Evaluate the Safety and Effectiveness of Anti-CD33 CAR NK Cell Therapy in Relapsed/Refractory Acute Myeloid Leukemia
NCT05008575 is registered in ClinicalTrials.gov with Xinqiao Hospital of Chongqing as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase I Study to Evaluate the Safety and Effectiveness of Anti-CD33 CAR NK Cell Therapy in Relapsed/Refractory Acute Myeloid Leukemia
- Lead sponsor
- Xinqiao Hospital of Chongqing
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- December 23, 2021
- Completion date
- December 1, 2023
- Enrollment
- 27 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.